Verrica Pharmaceuticals Inc. (VRCA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VRCA SEC filings page.
Verrica Pharmaceuticals Inc. (VRCA) reported $35.6M in revenue for fiscal year 2025, up 370.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 brought a sharp revenue rebound, smaller cash outflows, and a balance sheet no longer carrying reported long-term debt.
Revenue reached$35.6M in FY2025 from$7.6M in FY2024, while operating cash outflow also shrank materially. Since free cash flow matched operating cash flow at-$17.6M and capital expenditures were$0 , the improvement came from operations rather than heavy reinvestment.
Total liabilities fell from
The net loss exceeded the operating loss in FY2025, and
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Verrica Pharmaceuticals Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Verrica Pharmaceuticals Inc. held $30.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $17.6M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Verrica Pharmaceuticals Inc. scores 46/100 among other emerging companies.
Verrica Pharmaceuticals Inc. had 17M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Verrica Pharmaceuticals Inc. scores 83/100 among other emerging companies.
Verrica Pharmaceuticals Inc. spent $8.9M on research and development in fiscal year 2025, which was 18.5% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Verrica Pharmaceuticals Inc. scores 50/100 among other emerging companies.
Verrica Pharmaceuticals Inc. reported revenue of $35.6M in fiscal year 2025, against $7.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Verrica Pharmaceuticals Inc. scores 90/100 among other emerging companies.
Verrica Pharmaceuticals Inc.'s operations used $17.6M of cash in fiscal year 2025, against $60.9M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Verrica Pharmaceuticals Inc. scores 73/100 among other emerging companies.
Verrica Pharmaceuticals Inc.'s cash, cash equivalents and investments came to $30.1M at the end of fiscal year 2025, against $22.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Verrica Pharmaceuticals Inc. scores 66/100 among other emerging companies.
Verrica Pharmaceuticals Inc. scores -7.07, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($75.2M) relative to total liabilities ($22.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Verrica Pharmaceuticals Inc. passes 6 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Verrica Pharmaceuticals Inc. reported a net loss of $17.9M while operations used $17.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Verrica Pharmaceuticals Inc. reported an operating loss of $12.2M against $7.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Verrica Pharmaceuticals Inc. generated $5.9M in revenue in Q2 2026. This represents a decrease of 53.8% from the same quarter a year earlier. Against the prior quarter it is up 16.7%.
Verrica Pharmaceuticals Inc.'s EBITDA was -$13.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 892.7% from the same quarter a year earlier. Against the prior quarter it is down 35.1%.
Verrica Pharmaceuticals Inc. reported -$13.2M in net income in Q2 2026. This represents a decrease of 6547.5% from the same quarter a year earlier. Against the prior quarter it is down 35.9%.
Verrica Pharmaceuticals Inc. earned -$0.62 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 37.8%.
Cash & Balance Sheet
Verrica Pharmaceuticals Inc. held $11.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Verrica Pharmaceuticals Inc.'s ROE was -305.4% in Q2 2026, measuring profit generated per dollar of shareholder equity. Against the prior quarter it is down 245.1 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Verrica Pharmaceuticals Inc. invested $6.0M in research and development in Q2 2026. This represents an increase of 226.9% from the same quarter a year earlier. Against the prior quarter it is up 56.3%.
Not reported for Q2 2026.
Not reported for Q2 2026.
VRCA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9M-53.8% | $5.0M+46.1% | $5.1M+1380.2% | $14.3M | $12.7M+145.4% | $3.4M-10.1% | $344K-82.7% | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | $700K0.0% | $800K | $400K+33.3% |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | $2.7M-12.4% | -$456K | -$2.2M-183.3% |
| R&D Expenses | $6.0M+226.9% | $3.9M+69.0% | $2.5M+115.8% | $2.2M-8.3% | $1.8M-44.4% | $2.3M-53.8% | $1.2M-78.0% | $2.4M-63.1% |
| SG&A Expenses | $10.3M+16.9% | $10.0M+12.9% | $8.1M-17.8% | $9.4M-41.5% | $8.9M-46.4% | $8.8M-45.8% | $9.9M-41.9% | $16.1M-19.8% |
| Operating Income | -$13.1M-967.4% | -$9.7M-19.5% | -$7.2M+37.0% | $1.6M+107.9% | $1.5M+109.9% | -$8.1M+56.3% | -$11.4M+50.7% | -$20.7M+13.4% |
| EBITDA | -$13.0M-892.7% | -$9.6M-20.1% | -$7.1M+37.1% | $1.7M+108.5% | $1.6M+110.9% | -$8.0M+56.4% | -$11.3M+50.9% | -$20.4M+14.3% |
| Interest Expense | $164K-92.3% | $160K-92.7% | $1.3M-44.1% | $2.1M-11.9% | $2.1M-10.0% | $2.2M-5.0% | $2.3M+1.9% | $2.4M+43.4% |
| Net Income | -$13.2M-6547.5% | -$9.7M+0.6% | -$8.1M+50.1% | -$274K+98.8% | $204K+101.2% | -$9.7M+52.1% | -$16.2M+34.1% | -$22.9M+7.8% |
| EPS (Basic) | -$0.62-3200.0% | -$0.45+56.3% | -$0.65+64.3% | -$0.03+99.4% | $0.02+100.5% | -$1.03-134.1% | -$1.82-237.0% | -$4.88-803.7% |
| EPS (Diluted) | -$0.62 | -$0.45 | -$0.65+64.3% | -$0.03 | $0.02 | -$1.03 | -$1.82 | -$4.88 |
| Diluted Shares (Avg) | 21M | 21M | N/A | 9M | 9M | 9M | N/A | 5M |
Not reported in any period shown, so not listed: Income Tax.
VRCA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $36.0M-7.9% | $38.8M-8.0% | $47.1M-12.9% | $40.9M+24.2% | $39.1M-24.8% | $42.2M-36.4% | $54.1M-33.7% | $32.9M-66.1% |
| Current Assets | $32.6M-11.3% | $34.1M-13.5% | $42.5M-16.9% | $36.3M+28.7% | $36.8M-22.3% | $39.5M-35.7% | $51.2M-34.0% | $28.2M-69.3% |
| Cash & Equivalents | $11.2M-27.3% | $20.6M-30.4% | $30.1M-34.9% | $21.1M-8.1% | $15.4M-51.8% | $29.6M-39.5% | $46.3M-33.4% | $23.0M-72.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $2.7M+7.5% | $2.0M-19.7% | $2.2M-9.2% | $2.3M-10.8% | $2.5M-6.7% | $2.5M-1.6% | $2.5M+141.0% | $2.6M+826.2% |
| Accounts Receivable | $10.9M+19.0% | $7.7M+37.8% | $5.3M+10858.3% | $7.0M | $9.2M-8.3% | $5.6M-19.9% | $48K-98.9% | $0-100.0% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $31.7M-44.0% | $22.7M-62.6% | $22.4M-65.0% | $57.9M-13.5% | $56.6M-13.4% | $60.8M-6.2% | $64.0M+3.5% | $67.0M+22.1% |
| Current Liabilities | $22.4M-23.2% | $16.2M-44.8% | $16.4M-43.3% | $28.9M+37.5% | $29.2M+45.7% | $29.4M+51.8% | $29.0M+70.4% | $21.0M+84.9% |
| Non-Current Liabilities | $9.3M-66.1% | $6.5M-79.2% | $6.0M-83.0% | $29.0M-36.8% | $27.4M-39.5% | $31.4M-31.0% | $35.0M-21.9% | $46.0M+5.7% |
| Long-Term Debt | N/A | N/A | $0-100.0% | $21.6M-50.1% | $24.6M-42.5% | $27.8M-35.1% | $31.0M-27.7% | $43.3M+2.1% |
| Total Equity | $4.3M+124.6% | $16.1M+186.4% | $24.7M+350.9% | -$17.0M+50.0% | -$17.5M-31.5% | -$18.6M-1331.8% | -$9.9M-149.9% | -$34.1M-180.5% |
| Retained Earnings | -$347.7M-9.9% | -$334.6M-5.6% | -$324.9M-5.8% | -$316.8M-8.9% | -$316.6M-18.1% | -$316.8M-26.3% | -$307.0M-33.2% | -$290.8M-41.3% |
Not reported in any period shown, so not listed: Goodwill.
VRCA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$9.3M+7.6% | -$9.2M+27.7% | -$4.6M+71.4% | $9.7M+213.2% | -$10.0M+38.6% | -$12.7M+36.4% | -$16.1M-10.7% | -$8.6M+42.2% |
| Depreciation & Amortization | $128K+1.6% | $117K-14.0% | $114K-40.3% | $110K-61.7% | $126K-50.8% | $136K-48.5% | $191K+26.5% | $287K+184.2% |
| Stock-Based Compensation | $1.2M+36.6% | $897K-12.6% | N/A | $718K-65.9% | $888K-60.1% | $1.0M-50.5% | N/A | $2.1M-78.2% |
| Capital Expenditures | N/A | N/A | $0 | $0-100.0% | N/A | N/A | $0-100.0% | $16K-75.4% |
| Free Cash Flow | N/A | N/A | -$4.6M+71.4% | $9.7M+213.0% | N/A | N/A | -$16.1M-9.0% | -$8.6M+42.4% |
| Investing Cash Flow | $0 | $0 | $0-100.0% | $0+100.0% | $0+100.0% | $0 | $8K+103.5% | -$16K+75.4% |
| Financing Cash Flow | -$126K+97.0% | -$120K+97.0% | $13.6M-65.4% | -$4.0M-903.5% | -$4.2M-549.2% | -$4.1M-513.8% | $39.4M+146122.2% | -$397K-100.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VRCA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 79.7%-2.0pp | -132.6% | N/A |
| Operating Margin | -223.4% | -193.4% | -141.2% | 11.3% | 11.9% | -236.4% | -3316.9% | N/A |
| Net Margin | -224.4% | -192.8% | -158.8% | -1.9% | 1.6% | -283.3% | -4716.0% | N/A |
| Return on Equity | -305.4% | -60.3% | -32.7% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -36.5%-37.0pp | -25.0%-1.9pp | -17.2%+12.8pp | -0.7%+68.8pp | 0.5%+33.6pp | -23.1%+7.6pp | -30.0%+0.2pp | -69.4%-43.9pp |
| Current Ratio | 1.45+0.2x | 2.10+0.8x | 2.59+0.8x | 1.25-0.1x | 1.26-1.1x | 1.34-1.8x | 1.76-2.8x | 1.34-6.7x |
| Debt-to-Equity | 7.36 | 1.42 | 0.00 | N/A | N/A | N/A | N/A | N/A |
| Asset Turnover | 0.16-0.2x | 0.130.0x | 0.11+0.1x | 0.35+0.4x | 0.32+0.2x | 0.080.0x | 0.010.0x | -0.05-0.1x |
| FCF Margin | N/A | N/A | -90.2% | 67.5% | N/A | N/A | -4669.8% | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. VRCA | FY2025 | $35.6M | -$17.9M | -50.3% | $75.2M | 68/100 |
| PLUS THERAPEUTICS, Inc. PSTV | FY2025 | $5.2M | -$22.4M | N/A | $26.6M | 32/100 |
| Grace Therapeutics, Inc. GRCE | FY2026 | N/A | -$7.8M | N/A | $43.5M | — |
| Radiopharm Theranostics Limited RADX | FY2025 | $3.6M | -$38.3M | N/A | $20.7M | 20/100 |
| Outlook Therapeutics, Inc. OTLK | FY2025 | $1.4M | -$62.4M | N/A | $144.4M | 37/100 |
| CalciMedica, Inc. CALC | FY2025 | N/A | -$29.6M | N/A | $10.9M | — |
Where Verrica Pharmaceuticals Inc. Ranks
Frequently Asked Questions
What is Verrica Pharmaceuticals Inc.'s annual revenue?
Verrica Pharmaceuticals Inc. (VRCA) reported $35.6M in total revenue for fiscal year 2025. This represents a 370.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Verrica Pharmaceuticals Inc.'s revenue growing?
Verrica Pharmaceuticals Inc. (VRCA) revenue grew by 370.2% year-over-year, from $7.6M to $35.6M in fiscal year 2025.
Is Verrica Pharmaceuticals Inc. profitable?
No, Verrica Pharmaceuticals Inc. (VRCA) reported a net income of -$17.9M in fiscal year 2025, with a net profit margin of -50.3%.
What is Verrica Pharmaceuticals Inc.'s EBITDA?
Verrica Pharmaceuticals Inc. (VRCA) had EBITDA of -$11.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Verrica Pharmaceuticals Inc. have?
As of fiscal year 2025, Verrica Pharmaceuticals Inc. (VRCA) had $30.1M in cash and equivalents against $0 in long-term debt.
What is Verrica Pharmaceuticals Inc.'s operating margin?
Verrica Pharmaceuticals Inc. (VRCA) had an operating margin of -34.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Verrica Pharmaceuticals Inc.'s net profit margin?
Verrica Pharmaceuticals Inc. (VRCA) had a net profit margin of -50.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Verrica Pharmaceuticals Inc.'s return on equity (ROE)?
Verrica Pharmaceuticals Inc. (VRCA) has a return on equity of -72.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Verrica Pharmaceuticals Inc.'s free cash flow?
Verrica Pharmaceuticals Inc. (VRCA) recorded an outflow of $17.6M in free cash flow during fiscal year 2025. This represents a 71.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Verrica Pharmaceuticals Inc.'s operating cash flow?
Verrica Pharmaceuticals Inc. (VRCA) recorded an outflow of $17.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Verrica Pharmaceuticals Inc.'s total assets?
Verrica Pharmaceuticals Inc. (VRCA) had $47.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Verrica Pharmaceuticals Inc.'s capital expenditures?
Verrica Pharmaceuticals Inc. (VRCA) reported no capital expenditure during fiscal year 2025.
How much does Verrica Pharmaceuticals Inc. spend on research and development?
Verrica Pharmaceuticals Inc. (VRCA) invested $8.9M in research and development during fiscal year 2025.
What is Verrica Pharmaceuticals Inc.'s current ratio?
Verrica Pharmaceuticals Inc. (VRCA) had a current ratio of 2.59 as of fiscal year 2025, which is generally considered healthy.
What is Verrica Pharmaceuticals Inc.'s debt-to-equity ratio?
Verrica Pharmaceuticals Inc. (VRCA) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Verrica Pharmaceuticals Inc.'s return on assets (ROA)?
Verrica Pharmaceuticals Inc. (VRCA) had a return on assets of -38.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Verrica Pharmaceuticals Inc.'s P/E ratio?
Verrica Pharmaceuticals Inc. (VRCA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $75.2M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Verrica Pharmaceuticals Inc.'s price-to-sales ratio?
Verrica Pharmaceuticals Inc. (VRCA) trades at 2.5x sales, its market capitalization divided by revenue of $30.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $75.2M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Verrica Pharmaceuticals Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Verrica Pharmaceuticals Inc. (VRCA) held $30.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $17.6M over that year. Dividing the one by the other, the reported balance equals about 21 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Verrica Pharmaceuticals Inc.'s Altman Z-Score?
Verrica Pharmaceuticals Inc. (VRCA) has an Altman Z-Score of -7.07, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Verrica Pharmaceuticals Inc.'s Piotroski F-Score?
Verrica Pharmaceuticals Inc. (VRCA) has a Piotroski F-Score of 6 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Verrica Pharmaceuticals Inc.'s earnings high quality?
Verrica Pharmaceuticals Inc. (VRCA) reported a net loss of $17.9M while operations used $17.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Verrica Pharmaceuticals Inc. cover its interest payments?
Verrica Pharmaceuticals Inc. (VRCA) reported an operating loss of $12.2M against $7.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Verrica Pharmaceuticals Inc.?
Verrica Pharmaceuticals Inc. (VRCA) scores 68 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.